The milestone payment was made under the terms of the agreement between Purdue and Transcept for the commercialization of Intermezzo in the US.
Intermezzo (zolpidem tartrate) sublingual tablet is indicated in the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep.
Purdue has planned the launch of Intermezzo in the second quarter of 2012 and intends to invest around $100m to help in the progress of sales and marketing during the first year of commercialization.
The US FDA approved Intermezzo (zolpidem tartrate) sublingual tablet C-IV on 23 November 2011.